Meropenem is a carbapenem antibiotic for parenteral use that is stable to human dehydropeptidase-1. It exerts its antibacterial and bactericidal effects by interfering with the synthesis of bacterial cell walls. This product easily penetrates the bacterial cell wall, is stable to most β-lactamases, and has a high affinity for penicillin binding proteins (PBPs). Therefore, meropenem has a broad-spectrum antibacterial activity against aerobic and anaerobic bacteria. The antibacterial range includes: Gram-positive aerobic bacteria; Staphylococcus aureus (including β-lactamase-producing strains); Staphylococcus epidermidis (including β-lactamase-producing strains); Streptococcus pneumoniae; Streptococcus pyogenes; Streptococcus agalactiae; Streptococcus viridans; Enterococcus faecalis; Enterococcus ureus; Nocardia; Listeria monocytogenes; Gram-negative

No specific description provided

It is a new type of β-lactam antibiotic with a strong ability to inhibit bacterial cell wall synthesis and can kill most Gram-positive and Gram-negative bacteria.

It is a specific enzyme inhibitor that can block the metabolism of imipenem in the kidney, thereby increasing the concentration of imipenem parent drug in the urinary tract.

It is a new type of β-lactam antibiotic with a strong ability to inhibit bacterial cell wall synthesis and can kill most Gram-positive and Gram-negative bacteria.

It is a specific enzyme inhibitor that can block the metabolism of imipenem in the kidney, thereby increasing the concentration of imipenem parent drug in the urinary tract.

This product is a broad-spectrum β-lactam antibiotic with a strong ability to inhibit bacterial cell wall synthesis and can kill most Gram-positive and Gram-negative bacteria.

It is a specific enzyme inhibitor that can block the metabolism of imipenem in the kidney, thereby increasing the concentration of imipenem parent drug in the urinary tract.